Herpes Zoster Ophthalmicus

This analysis of the ZEDS trial suggests that valacyclovir prophylaxis offers temporally localized protection against recurrent ocular inflammation in herpes zoster ophthalmicus, supporting one-year suppressive therapy despite non-significant primary outcomes.